The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

The average age of men who get diagnosed is 67.

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...